The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women and ...

The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for treating uncomplicated urinary tract infections (uUTIs) in adult females ...

GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly becoming treatment-resistant.

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

On March 25, the U.S. Food and Drug Administration (FDA) approved the first new antibiotic to treat UTIs in 30 years. The medication, gepotidacin, targets E. coli bacteria, which is responsible for ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

GSK’s oral antibiotic Blujepa (gepotidacin) has been approved by the US Food and Drug Administration (FDA) to treat uncomplicated urinary tract infections (uUTIs). The drug, which is the first in a ...

The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be ...

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract infections caused ...

GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

London: British pharmaceutical major GlaxoSmithKline (GSK) has failed to meet the required regulatory and ethical standards ...